|
1
|
Khan A, Farah CS, Savage NW, Walsh LJ,
Harbrow DJ and Sugerman PB: Th1 cytokines in oral lichen planus. J
Oral Pathol Med. 32:77–83. 2003. View Article : Google Scholar
|
|
2
|
Gupta S and Jawanda MK: Oral Lichen
Planus: An update on etiology, pathogenesis, clinical presentation,
diagnosis and management. Indian J Dermatol. 60:222–229. 2015.
View Article : Google Scholar :
|
|
3
|
Dudhia BB, Dudhia SB, Patel PS and Jani
YV: Oral lichen planus to oral lichenoid lesions: Evolution or
revolution. J Oral Maxillofac Pathol. 19:364–370. 2015. View Article : Google Scholar :
|
|
4
|
Ashkar S, Weber GF, Panoutsakopoulou V,
Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, Denhardt DT,
Glimcher MJ and Cantor H: Eta-1 (osteopontin): An early component
of type-1 (cell-mediated) immunity. Science. 287:860–864. 2000.
View Article : Google Scholar
|
|
5
|
Weber GF, Ashkar S, Glimcher MJ and Cantor
H: Receptor-ligand interaction between CD44 and osteopontin
(Eta-1). Science. 271:509–512. 1996. View Article : Google Scholar
|
|
6
|
Chabas D, Baranzini SE, Mitchell D,
Bernard CC, Rittling SR, Denhardt DT, Sobel RA, Lock C, Karpuj M,
Pedotti R, et al: The influence of the proinflammatory cytokine,
osteopontin, on autoimmune demyelinating disease. Science.
294:1731–1735. 2001. View Article : Google Scholar
|
|
7
|
Sakata M, Tsuruha JI, Masuko-Hongo K,
Nakamura H, Matsui T, Sudo A, Nishioka K and Kato T: Autoantibodies
to osteopontin in patients with osteoarthritis and rheumatoid
arthritis. J Rheumatol. 28:1492–1495. 2001.
|
|
8
|
Chiocchetti A, Indelicato M, Bensi T,
Mesturini R, Giordano M, Sametti S, Castelli L, Bottarel F,
Mazzarino MC, Garbarini L, et al: High levels of osteopontin
associated with polymorphisms in its gene are a risk factor for
development of autoimmunity/lymphoproliferation. Blood.
103:1376–1382. 2004. View Article : Google Scholar
|
|
9
|
Zhou ZT, Wei BJ and Shi P: Osteopontin
expression in oral lichen planus. J Oral Pathol Med. 37:94–98.
2008. View Article : Google Scholar
|
|
10
|
Santarelli A, Mascitti M, Rubini C,
Bambini F, Zizzi A, Offidani A, Ganzetti G, Laino L, Cicciù M and
Lo Muzio L: Active inflammatory biomarkers in oral lichen planus.
Int J Immunopathol Pharmacol. 28:562–568. 2015. View Article : Google Scholar
|
|
11
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Rese. 19:92–105. 2009. View Article : Google Scholar
|
|
12
|
Gassling V, Hampe J, Açil Y, Braesen JH,
Wiltfang J and Häsler R: Disease-associated miRNA-mRNA networks in
oral lichen planus. PLoS One. 8:e630152013. View Article : Google Scholar :
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
14
|
van der Waal I, Schepman KP and van der
Meij EH: A modified classification and staging system for oral
leukoplakia. Oral Oncol. 36:264–266. 2000. View Article : Google Scholar
|
|
15
|
Fischer AH, Jacobson KA, Rose J and Zeller
R: Hematoxylin and eosin staining of tissue and cell sections. CSH
Protoc. 2008:pdb prot4986. 2008.
|
|
16
|
Chanmee T, Ontong P, Kimata K and Itano N:
Key roles of Hyaluronan and its CD44 receptor in the stemness and
survival of cancer stem cells. Front Oncol. 5:1802015. View Article : Google Scholar :
|
|
17
|
Chaiyarit P, Thongprasom K, Satayut S,
Dhanuthai K, Piboonratanakit P, Phothipakdee P, Subarnbhesaj A,
Limlertmongkol S and Chaimusig M: Alteration of the expression of
CD44 [corrected] isoforms in oral epithelia and saliva from
patients with oral lichen planus. J Clin Immunol. 28:26–34. 2008.
View Article : Google Scholar
|
|
18
|
Liu GX, Sun JT, Yang MX, Qi XM, Shao QQ,
Xie Q, Qu X, Wei FC and Sun SZ: OPN promotes survival of activated
T cells by up-regulating CD44 in patients with oral lichen planus.
Clin Immunol. 138:291–298. 2011. View Article : Google Scholar
|
|
19
|
Kuninty PR, Bojmar L, Tjomsland V, Larsson
M, Storm G, Östman A, Sandström P and Prakash J: MicroRNA-199a and
−214 as potential therapeutic targets in pancreatic stellate cells
in pancreatic tumor. Oncotarget. 7:16396–16408. 2016. View Article : Google Scholar :
|
|
20
|
Liu Y, Zhou H, Ma L, Hou Y, Pan J, Sun C,
Yang Y and Zhang J: MiR-214 suppressed ovarian cancer and
negatively regulated semaphorin 4D. Tumour Biol. 37:8239–8248.
2016. View Article : Google Scholar
|
|
21
|
Xu Y and Lu S: Regulation of
β-catenin-mediated esophageal cancer growth and invasion by
miR-214. Am J Transl Res. 7:2316–2325. 2015.
|
|
22
|
Yu X, Luo A, Liu Y, Wang S, Li Y, Shi W,
Liu Z and Qu X: MiR-214 increases the sensitivity of breast cancer
cells to tamoxifen and fulvestrant through inhibition of autophagy.
Mol Cancer. 14:2082015. View Article : Google Scholar :
|
|
23
|
Phatak P, Byrnes KA, Mansour D, Liu L, Cao
S, Li R, Rao JN, Turner DJ, Wang JY and Donahue JM: Overexpression
of miR-214-3p in esophageal squamous cancer cells enhances
sensitivity to cisplatin by targeting survivin directly and
indirectly through CUG-BP1. Oncogene. 35:2087–2097. 2016.
View Article : Google Scholar
|
